Summary of economic evaluations of urate lowering therapies in gout.
| Study | Study Design | Study Details | Risk of Bias |
|---|---|---|---|
| Stevenson 2011 & NICE 200847,48 | Cost-effectiveness analysis | Manufacturer supplied febuxostat economic analyses | High |
| Ferraz 199549 | Cost-effectiveness analysis | 1993 Canadian population, decision analysis model analysing initiation of urate lowering drug (ULD) vs non ULD initiation from a societal perspective regarding costs with a 1 year time horizon | Low |